SCC水平对宫颈癌和卵巢癌患者手术联合新辅助化疗敏感性及疗效预测价值的比较分析  

Comparative Analysis of SCC Levels in Predicting Neoadjuvant Chemotherapy Sensitivity and Efficacy of Cervical Cancer and Ovarian Cancer after Surgery

作　　者：陈君茂 徐策 

机构地区：[1]湖北省武穴市第一人民医院,435400

出　　处：《实用癌症杂志》2018年第3期500-502,506,共4页The Practical Journal of Cancer

摘　　要：目的探讨接受新辅助化疗和根治性手术的宫颈癌患者和卵巢癌患者SCC-Ag水平的变化情况,及其对与预后的预测作用。方法选取宫颈癌患者和卵巢癌患者252例作为研究对象,其中宫颈癌患者127例,卵巢癌患者125例;收集手术联合接受新辅助化疗前后患者相关基线信息以及血清SCC水平以及SCC-Ag阳性信息,并进行相关水平的对比分析,全部研究对象随访5年。采用酶联免疫吸附法检测血清SCC等水平。评价手术联合新辅助化疗前后SCC-Ag水平的变化情况,及其对预后的预测作用。采用SPSS16.0统计软件包完成统计分析。结果手术联合新辅助化疗治疗前,宫颈癌患者血清中SCC阳性率为100.00%,手术联合新辅助化疗后阳性率降至17.32%,P<0.01,有105例患者转阴。卵巢癌患者治疗前后SCC阳性率分别为14.40%和5.60%,P<0.01,有11例患者转阴。治疗前和治疗后,SCC阳性率均见宫颈癌组较卵巢癌组高,P<0.01。另外,SCC-Ag水平在宫颈癌患者中由治疗前的(3.79±0.76)ng/m L降至治疗后的(3.31±0.72)ng/m L,P<0.01。卵巢癌组治疗后SCC-Ag表达水平也显著下降,P<0.01。2种肿瘤患者之间比较,SCC-Ag也均见在宫颈癌组水平较高。SCC-Ag>3.5 ng/m L的宫颈癌患者的3年生存率较SCC-Ag≤3.5 ng/m L组患者差;且SCC-Ag高表达患者3年和5年生存率均显示宫颈癌组要低于卵巢癌组,SCC-Ag低表达患者中也发现了生存率的类似上述变化状态。结论 SCC不仅作为宫颈癌的肿瘤标志物在早期宫颈癌诊断中发挥重要作用,而且在卵巢癌的治疗评价中也具有一定的临床价值,其还可同时作为宫颈癌和卵巢癌的预后评价指标。Objective To investigate the changes of SCC-Ag levels in patients with cervical cancer and ovarian cancer who underwent neoadjuvant chemotherapy and radical surgery,and their predictive effects on prognosis. Methods A total of 252 patients with cervical cancer and ovarian cancer were enrolled in ttlis study. There were 127 cases of cervical cancer and 125 cases of ovarian cancer. The baseline information and serum SCC level and SCC-Ag positive information were collected before and after neoadjuvant chemotherapy, And the correlation level was analyzed. All the subjects were foUowed up for 5 years. Serum SCC levels were measured by enzyme-linked immunosorbent assay （ELISA）. To evaluate the changes of SCC-Ag level before and after neoadjuvant chemotherapy and its prognostic effect. Statistical analysis was performed using SPSS16.0 statistical software package. Resuits The positive rate of serum SCC was 100.00% in patients with cervical cancer before operation and neoadjuvant chemotherapy. The positive rate of surgery was 12.3% ,P 〈0.01 ,and 105 cases were negative. The positive rate of SCC was 14.40% and 5.60% in patients with ovarian cancer before and after treatment,P 〈 0.01,11 cases were negative. Before and after treatment, the positive rate of SCC was higher in cervical cancer group （ P 〈 0.01 ）. In addition, the level of SCC-Ag was reduced from （3.79 ±0.76） ng/mL to （3.31 ±0.72） ng/mL before treatment （P 〈0.01 ） in cervical cancer patients. The level of SCC-Ag expression in ovarian cancer group was also significantly decreased, and the level of SCC-Ag was also higher in cervical cancer group than in P 〈 0.01.2 tumor patients. The 3-year survival rate of patients with SCC-Ag 〉 3.5 ng/mL was worse than that of patients with SCC-Ag≤3.5 ng/mL. The 3-year and 5-year survival rates of patients with SCC-Ag high expression in cervical cancer group were lower than ovarian cancer group. The same with SCC-Ag low ecpression patients. Conclusion SCC plays an important role not only in th

关 键 词：宫颈癌 卵巢癌 手术联合新辅助化疗 鳞状上皮细胞癌抗原 

分 类 号：R737.33[医药卫生—肿瘤] R737.31[医药卫生—临床医学]